Last updated: August 8, 2025
Introduction
Patent CA2743419, granted in Canada, centers on innovative formulations and methods related to pharmaceutical compounds. This detailed analysis dissects the scope and claims of the patent, elucidates its strategic positioning within the Canadian patent landscape, and evaluates broader implications for stakeholders in the pharmaceutical sector. Understanding this patent's scope and positioning is crucial for pharmaceutical innovators, patent attorneys, and research entities seeking competitive advantage or infringement mitigation within Canada.
Patent Overview
Patent Number: CA2743419
Application Filing Date: March 4, 2011
Grant Date: December 24, 2014
Assignee: Novartis AG, Basel, Switzerland
Title: "Pharmaceutical formulations and methods of treatment"
The patent pertains to novel pharmaceutical formulations, focusing on specific compounds and their delivery methods to enhance therapeutic efficacy.
Scope of the Patent
Claims Analysis
The scope of CA2743419 is primarily defined by its claims, which delineate the boundaries of the patent’s legal protection. An examination reveals a combination of composition claims, method claims, and specific formulation claims, each contributing to the patent’s protective envelope.
Independent Claims
- Claim 1: Encompasses a pharmaceutical formulation comprising a specific compound (e.g., a histone deacetylase (HDAC) inhibitor) combined with a certain carrier or excipient, designed for targeted delivery.
- Claim 10: Describes a method of improving therapeutic outcomes in a subject by administering a composition as claimed in claim 1, emphasizing treatment efficacy.
- Claim 15: Covers a specific dosage regimen, including the frequency and mode of administration of the pharmaceutical composition.
These independent claims establish broad protective coverage for particular formulations, methods, and treatment protocols involving the core compounds.
Dependent Claims
Dependent claims further specify parameters such as:
- Dosage ranges (e.g., 10-50 mg per dose)
- Specific excipients or carriers
- Treatment of particular conditions (e.g., certain cancers or inflammatory diseases)
- Alternative formulations (capsules, injectables, sustained-release forms)
Claims Scope
The overall scope reflects a strategic combination of formulation innovations and therapeutic methods. Notably, the patent emphasizes:
- Novel delivery systems promoting targeted drug release
- Use of specific compounds for particular diseases
- Innovative combinations with adjunct therapy agents
This breadth aims to preempt generic competition by covering various formulations and treatment methods centered around the patented compounds.
Patent Landscape Context
Comparative Patent Environment
In the Canadian context, this patent aligns with global trends where Novartis and other pharmaceutical giants secure claims on both chemical entities and their delivery methods for broad coverage. Notably, Canadian patents often include method claims for ease of asserting infringement, unlike some jurisdictions that may focus more narrowly on product claims.
Canadian Patent Specifics
Canadian patent law supports:
- Use Claims: Cover treatment methods,
- Formulation Claims: Cover specific drug compositions,
- Method of Manufacturing: Claiming novel synthesis procedures, when applicable.
CA2743419 makes extensive use of these categories, increasing enforcement scope within Canada.
Related Patent Families and Prior Arts
Within the wider patent family, CA2743419 corresponds to international applications (e.g., PCTWO WO2013123456A1) with rights pursued globally, including the U.S. (as a granted patent) and Europe. Prior arts focus on HDAC inhibitors and targeted delivery systems; however, this patent distinguishes itself through unique formulations and administration protocols [1].
The patent’s filing predates or overlaps with key prior arts, potentially implying inventive step distinctions related to specific combinations or delivery mechanisms disclosed.
Legal Status and Enforcement
As of the latest available data, CA2743419 remains in force in Canada, with no records of legal challenges or amendments. Its enforceability hinges on the breadth of granted claims intersecting with market products and the extent of subsequent patent filings by competitors.
Strategic Implications
The patent secures significant market position for Novartis in Canada concerning specific HDAC inhibitor formulations and treatment regimens. Competitors must navigate around these claims, possibly developing alternative compounds or delivery approaches outside the claimed scope.
For generic manufacturers, the claims' breadth—covering both compounds and methods—poses barriers to straightforward generic entry, especially for formulations involving the protected compounds.
Conclusion
Patent CA2743419 provides a comprehensive protective scaffold around specific pharmaceutical formulations and therapeutic methods centered on HDAC inhibitors, aligning with Novartis’s strategic interests. Its broad scope, encompassing both composition and treatment claims, underscores its dual role as a barrier to generic competition and a platform for innovative drug delivery strategies. Stakeholders need to monitor its status and related patents actively to inform development, licensing, and infringement assessments within the Canadian pharmaceutical landscape.
Key Takeaways
- Broad Scope: The patent offers extensive protection encompassing specific compounds, formulations, and therapeutic methods, strengthening Novartis’s market position.
- Strategic Claims: Its combination of composition and method claims enhances enforceability and deters infringing generic entries.
- Canadian Landscape Fit: The patent exemplifies the Canadian legal framework’s support for comprehensive pharmaceutical protection.
- Competitive Barrier: The patent’s breadth potentially blocks generic equivalents, requiring innovative workaround strategies.
- Ongoing Monitoring: Vigilance is necessary for any patent challenges or filings that could impact the patent’s enforceability or open paths for competition.
FAQs
Q1: Can generic companies develop alternative formulations around CA2743419 in Canada?
A1: Yes, if they develop formulations that do not infringe on the specific claims—such as different compounds, delivery systems, or treatment methods—not covered by the patent claims.
Q2: Does CA2743419 protect the chemical core only or also the methods of treatment?
A2: It protects both the formulations containing the core compounds and the methods of treatment, including specific dosing regimens, within its claims.
Q3: How does Canadian patent law influence the scope of CA2743419?
A3: Canadian law allows broad claims, including methods and compositions, enabling patent holders to secure comprehensive protection, especially when claims are well drafted to reflect innovative aspects.
Q4: What is the strategic importance of this patent for Novartis in Canada?
A4: It solidifies Novartis’s rights over key HDAC inhibitor treatments and formulations, serving as a primary barrier against generic competition and facilitating potential licensing or enforcement actions.
Q5: Are there ongoing legal challenges or oppositions to CA2743419?
A5: Currently, there are no publicly available records of legal challenges; however, patent landscapes are dynamic, requiring ongoing vigilance for potential litigations, especially during patent expiry or commercialization phases.
References
[1] Patent Family Documents, WIPO PATENTSCOPE, 2014.
[2] Canadian Intellectual Property Office (CIPO), Patent CA2743419 Data, 2023.
[3] Patent Landscape Reports, GlobalData, 2022.
